



Universal Hepatitis B Vaccination in Adults Aged 19–59 Years: Updated Recommendations of the ACIP— United States, 2022

Noele Nelson, MD, PhD MPH
Chief, Prevention Branch, Division of Viral Hepatitis

The Summit Weekly Update
April 28, 2022

1

1

Outline

- ACIP hepatitis B vaccine recommendations
- Draft CDC hepatitis B testing and screening recommendations
- Promotion and implementation of new recommendations

2

2


Overview of New ACIP Hepatitis B Vaccine Recommendations

3

Advances in adult hepatitis B vaccine recommendations

Updated hepatitis B vaccination recommendations published in April 2022: A move away from risk-based approaches

- All adults 19-59 years and adults ≥ 60 years with risk factors **should** receive hepatitis B vaccines
- Adults ≥ 60 years without known risk factors **may** receive hepatitis B vaccines




Weng MK, Doshani M, Khan MA, Frey S, Ault K, Moore KL, Hall EW, Morgan RL, Campos-Outcalt D, Wester C, Nelson NP. MMWR 2022 Apr 1;71(13):477-483. doi: 10.15585/mmwr.mm7113a1.

4

4


Risk-based hepatitis B immunization among adults: a partial success

- Initial decreases in new hep B infections plateaued 10 years ago
- Rates are now highest among adults
- Rates have *increased* among adults ≥ 40 years of age



5


HepB vaccination coverage decreased in older-aged adults with ≥ 1 risk factor*



6

Limitations of a risk-based approach

Availability of information regarding risk behaviors or exposures associated with reported cases of acute hepatitis B virus infection
— United States, 2019



2/3 of reported cases were either missing risk data or reported no identified risk

Source: <https://www.cdc.gov/hepatitis/statistics/2019surveillance/index.htm>


7

7

Health equity: Disparities could be reduced with a universal adult HepB recommendation

- Rates of HBV infection for children and adolescents of all races/ethnicities converged to a lower rate when a universal vaccination strategy was implemented for children $\leq 18y$.^{1, 2}
- Current rates among Black American adults are now up to 3x those of Asian/Pacific Islander and Hispanic groups.¹
- Racial/ethnic disparities remain in hepatitis B virus infections.

Rates of reported acute HBV infections, by race/ethnicity—United States, 2004–2019



¹ <https://www.cdc.gov/hepatitis/statistics/2019surveillance/HepB.htm>

² Wasley et al. MMWR. 2008

8

8

Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults

Eric W. Hall,^{1,2} Mark K. Weng,³ Aaron M. Harris,³ Sarah Schillie,⁴ Noele P. Nelson,³ Ismael R. Ortega-Sanchez,⁴ Elizabeth Rosenthal,⁵ Patrick S. Sullivan,² Ben Lopman,² Jeb Jones,² Heather Bradley,⁶ and Eli S. Rosenberg,^{5,7}

¹School of Public Health, Oregon Health and Science University, Portland, Oregon, USA, ²Emory University, Rollins School of Public Health, Department of Epidemiology, Atlanta, Georgia, USA, ³National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, ⁴National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA, ⁵Department of Epidemiology and Biostatistics, School of Public Health, University at Albany, Rensselaer, New York, USA, ⁶Department of Epidemiology and Biostatistics, School of Public Health, Georgia State University, Atlanta, Georgia, USA, and ⁷New York State Department of Health, Albany, New York, USA

Hall EW. et al. J Infect Dis. 2022 Mar 9:jiac088. doi: 10.1093/infdis/jiac088.

Benefits: universal adult vaccination against HBV infection among general population adults, United States

- Increase percent of people protected
- Avert additional HBV-related outcomes

Outcome	3-dose Strategy, n (IQR)	2-dose Strategy, n (IQR)
Vaccination outcomes		
% protected, current strategy	23.7 (23.7–23.7)	23.7 (23.7–23.7)
% protected, intervention strategy	44.9 (44.9–44.9)	45.7 (45.6–45.7)
Epidemiological outcomes		
% of chronic HBV infections averted	24.2 (18.2–30.0)	24.0 (18.0–29.7)
% of HBV deaths	22.8 (17.3–27.3)	22.2 (16.7–27.0)

Considerations

- **Evidence supports a universal HepB vaccination approach over risk-based vaccination approaches toward lowering barriers to vaccination.**
- **Universal hepatitis B vaccination recommendation among adults will provide best chance of achieving HBV elimination goals¹**
- **More vaccine tools available than when risk-based policy was first recommended**
 - Two 3-dose monovalent vaccines are available; safe, effective with long-term immunogenicity (>35 y)
 - One 2-dose vaccine is available; safe and effective
 - One 3-dose, 3-antigen vaccine recently FDA approved and ACIP recommended

¹ National Academies of Science, Engineering, and Medicine. <https://www.nationalacademies.org/our-work/a-national-strategy-for-the-elimination-of-hepatitis-b-and-c>

Overview of Draft CDC Recommendations for Hepatitis B Screening and Testing

Advances in adult hepatitis B screening and testing recommendations

Screening and testing guidelines posted in the Federal Register for public comment

- Proposed recommendation: **at least once in a lifetime for adults aged ≥ 18 years**
- Public comment closes June 3, 2022



<https://www.federalregister.gov/d/2022-07050>

https://www.cdc.gov/hepatitis/policy/pdfs/CDC_Updated_HBV_Guidelines_Presentation_508.pdf

13

Next Steps

- **Spring 2022: Review and respond to peer review and FRN comments (60-day comment period)**
- **Summer 2022: Submit the revised guidelines to CDC clearance**
- **By end of 2022:**
 - MMWR publication
 - Integrated hepatitis B testing and vaccination guidance

14

Promotion and Implementation

15

Promotion of ACIP Adult Hepatitis B Vaccination Recommendations


- **MMWR Promotion**

- **Increase awareness via webinars**
 - National Viral Hepatitis Education, Awareness, and Capacity Building for Communities and Providers Cooperative Agreement Part B recipient meeting (University of Washington & WebMD) – January 10, 2022
 - National Adult and Influenza Immunization Summit (NAIIS) weekly call – January 13, 2022
 - CDC Immunization Services Division Program Operations Branch recipient call (Immunization Managers) – January 19, 2022
 - Indian Health Service Grand Rounds – March 23, 2022
 - Hepatitis B Foundation, NASTAD and AIM webinar – April 25, 2022
 - Hepatitis B Foundation HBV ECHO – April 28, 2022
 - More to come...

16

Provider Outreach - Resources for Clinicians

- **CDC's Current Issues in Immunization April 20 Webinar**
 - Immunization Update on ACIP Recommendations for Hepatitis B, Pneumococcal and Zoster Vaccines. Dr. Mark Weng, MD, from CDC's Viral Hepatitis program participated in this presentation.
- **University of Washington – Hepatitis B Online**
 - Free continuing medical education, tools, and resources for clinicians, pharmacists and others about hepatitis B, including vaccination
 - Univ of Washington Hepatitis B online can be found at www.hepatitisB.uw.edu
- **Immunize.org Resources**
 - Immunize.org updated its popular, "Ask the Experts: Hepatitis B" webpage, which includes an extensive list of clinical questions and answers incorporating the updated hepatitis B vaccination recommendation.
 - [Standing Orders For Administering Hepatitis B Vaccine to Adults \(immunize.org\)](http://www.immunize.org)




17



HEPATITIS AWARENESS MONTH

Ways to Promote Hepatitis Awareness Month 2022:

- Use and share our Awareness Month content and social media toolkit
 - Visit www.cdc.gov/hepatitis
 - Click on Hepatitis Awareness Month box at the top
- Engage with us on Twitter [@cdchep](https://twitter.com/cdchep)
- Use the Awareness Month hashtags:
[#HepatitisAwarenessMonth](https://twitter.com/hashtag/HepatitisAwarenessMonth)
[#Hepatitis](https://twitter.com/hashtag/Hepatitis) [#HepAware2022](https://twitter.com/hashtag/HepAware2022)



18

Implementation

- **ACIP Adult Hepatitis B Vaccination Recommendations AND CDC Recommendations for Hepatitis B Screening and Testing**
 - Explore model hepatitis B programs to screen, vaccinate or link-to-care following the new universal screening and vaccination recommendations and associated clinical considerations
 - Leverage Integrated Viral Hepatitis Surveillance and Prevention Funding for Health Departments (IVHSP) - CDC-RFA-PS21-2103
 - Component 2: Core Viral Hepatitis Prevention Activities
 - Utilize CDC partnerships and cooperative agreements for public and provider education
 - Engage with federal and non-federal partners to explore implementation opportunities
 - Improve immunization practices through collaboration, syndemic approaches, and innovation

19

Acknowledgements

- **ACIP Hepatitis Work Group and MMWR co-authors (Mark Weng)**
- **CDC Hepatitis B Testing/ Guideline work group and steering committee (Erin Conners)**
- **Division of Viral Hepatitis Policy and Communications (Kari Sapsis)**

20

20

Thank you

Additional references available upon request
Noele Nelson, xdg9@cdc.gov

For more information, contact CDC
1-800-CDC-INFO (232-4636)
TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

